

AMENDED CLAIMS

[received by the International Bureau on 07 September 2005 (07.09.05),
original claims 1 to 4 replaced by new claims 1 to 4 (1 page)]

What is claimed is:

1. A method of identifying a candidate psychiatric patient for treatment with atypical antipsychotic or antidepressant medication that acts at a D2 dopamine receptor (DRD2) or influences D2 dopamine receptor density, the method comprising:
 - 5 determining whether the patient's DRD2 genotype is Taq1A allele positive (A1+) or Taq1A allele negative (A1-); wherein:
 - an A1+ genotype is indicative of a candidate for treatment with high dose high DRD2 binding atypical antipsychotics and/or SSRIs that increase D2 dopamine receptor
10 density; and
 - an A1- genotype is indicative of a candidate for treatment with low dose high or low D2 dopamine receptor binding atypical antipsychotics or alternative antidepressant.
2. The method of claim 1, wherein the psychiatric patient suffers from schizophrenia.
- 15 3. The method of claim 1, wherein the patient suffers from post-traumatic stress disorder (PTSD), depression, social anxiety or mixed anxiety and depressive states.
4. The method of claim 1 when the patient suffers from Parkinson's disease.